Summary
Global Markets Direct’s, ‘Pruritus - Pipeline Review, H1 2016’, provides an overview of the Pruritus pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
- The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pruritus
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AlbireoPharma
Amorepacific Corporation
Cara Therapeutics, Inc.
Chugai Pharmaceutical Co., Ltd.
Creabilis SA
ELORAC, Inc.
Faes Farma, SA
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
LEO Pharma A/S
Merck & Co., Inc.
NeRRe Therapeutics Ltd
Nippon Shinyaku Co., Ltd.
Patara Pharma, Inc.
Phosphagenics Limited
RDD Pharma Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
Shionogi & Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Tioga Pharmaceuticals, Inc.
Trevi Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pruritus Overview 10
Therapeutics Development 11
Pipeline Products for Pruritus - Overview 11
Pipeline Products for Pruritus - Comparative Analysis 12
Pruritus - Therapeutics under Development by Companies 13
Pruritus - Therapeutics under Investigation by Universities/Institutes 15
Pruritus - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pruritus - Products under Development by Companies 19
Pruritus - Products under Investigation by Universities/Institutes 21
Pruritus - Companies Involved in Therapeutics Development 22
AlbireoPharma 22
Amorepacific Corporation 23
Cara Therapeutics, Inc. 24
Chugai Pharmaceutical Co., Ltd. 25
Creabilis SA 26
ELORAC, Inc. 27
Faes Farma, SA 28
GlaxoSmithKline Plc 29
Hydra Biosciences, Inc. 30
LEO Pharma A/S 31
Merck & Co., Inc. 32
NeRRe Therapeutics Ltd 33
Nippon Shinyaku Co., Ltd. 34
Patara Pharma, Inc. 35
Phosphagenics Limited 36
RDD Pharma Ltd. 37
Sanwa Kagaku Kenkyusho Co., Ltd. 38
Shionogi & Co., Ltd. 39
Sumitomo Dainippon Pharma Co., Ltd. 40
Tioga Pharmaceuticals, Inc. 41
Trevi Therapeutics, Inc. 42
Vanda Pharmaceuticals Inc. 43
Pruritus - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
A-4250 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
aprepitant - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
asimadoline - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ASN-008 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
bilastine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
C-745 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CR-845 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
cromolyn sodium - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CT-327 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CT-340 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
desloratadine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
GSK-2330672 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
lidocaine hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
nalbuphine hydrochloride ER - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
naloxone hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
nemolizumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NS-141 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
orvepitant maleate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PAC-14028 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RDD-1609 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
serlopitant - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SK-1405 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Agonize CB2 for Pruritus - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecule to Inhibit Substance P for Pruritus - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecules to Inhibit Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
tradipitant - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Pruritus - Recent Pipeline Updates 92
Pruritus - Dormant Projects 106
Pruritus - Discontinued Products 107
Pruritus - Product Development Milestones 108
Featured News & Press Releases 108
Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting 108
Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference 109
Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain 109
Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis 109
May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 110
Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids 111
Mar 19, 2015: Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 111
Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 112
Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration 113
Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients 114
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 116
Disclaimer 117
List of Tables
Number of Products under Development for Pruritus, H1 2016 11
Number of Products under Development for Pruritus - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Pruritus - Pipeline by AlbireoPharma, H1 2016 22
Pruritus - Pipeline by Amorepacific Corporation, H1 2016 23
Pruritus - Pipeline by Cara Therapeutics, Inc., H1 2016 24
Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 25
Pruritus - Pipeline by Creabilis SA, H1 2016 26
Pruritus - Pipeline by ELORAC, Inc., H1 2016 27
Pruritus - Pipeline by Faes Farma, SA, H1 2016 28
Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2016 29
Pruritus - Pipeline by Hydra Biosciences, Inc., H1 2016 30
Pruritus - Pipeline by LEO Pharma A/S, H1 2016 31
Pruritus - Pipeline by Merck & Co., Inc., H1 2016 32
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H1 2016 33
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 34
Pruritus - Pipeline by Patara Pharma, Inc., H1 2016 35
Pruritus - Pipeline by Phosphagenics Limited, H1 2016 36
Pruritus - Pipeline by RDD Pharma Ltd., H1 2016 37
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 38
Pruritus - Pipeline by Shionogi & Co., Ltd., H1 2016 39
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 40
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H1 2016 41
Pruritus - Pipeline by Trevi Therapeutics, Inc., H1 2016 42
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 43
Assessment by Monotherapy Products, H1 2016 44
Number of Products by Stage and Target, H1 2016 46
Number of Products by Stage and Mechanism of Action, H1 2016 48
Number of Products by Stage and Route of Administration, H1 2016 50
Number of Products by Stage and Molecule Type, H1 2016 52
Pruritus Therapeutics - Recent Pipeline Updates, H1 2016 92
Pruritus - Dormant Projects, H1 2016 106
Pruritus - Discontinued Products, H1 2016 107
List of Figures
Number of Products under Development for Pruritus, H1 2016 11
Number of Products under Development for Pruritus - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 44
Number of Products by Top 10 Targets, H1 2016 45
Number of Products by Stage and Top 10 Targets, H1 2016 45
Number of Products by Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Routes of Administration, H1 2016 49
Number of Products by Stage and Routes of Administration, H1 2016 49
Number of Products by Molecule Types, H1 2016 51
Number of Products by Stage and Molecule Types, H1 2016 51
